Boston Medical Center: Amyloidosis trials

The registry lists 10 Amyloidosis studies with Boston Medical Center as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 1 2Phase 2 8Phase 3 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis PatientsTerminatedNCT02994784Phase 2Results posted
• Daratumumab for the Treatment of Patients With AL AmyloidosisCompletedNCT02841033Phase 1/2Results posted
• Trial of High Dose Melphalan/Stem Cell Transplant With or Without BortezomibTerminatedNCT02489500Phase 3Results posted
• A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL AmyloidosisCompletedNCT01570387Phase 1/2Results posted
• Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) AmyloidosisCompletedNCT01083316Phase 2Results posted
• Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00790647Phase 2Results posted
• Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00679367Phase 2Results posted
• 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) AmyloidosisTerminatedNCT00075608Phase 2Results posted
• Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL AmyloidosisCompletedNCT02716103
• Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) AmyloidosisCompletedNCT00075621Phase 2